Human Fungal Infections: Pathogens, Current Antifungal Therapies, Antifungal Resistance, and Probiotics: A Literature Review
Immuno · 06.11.2026 · 6 (4) · 76
DOI: 10.3390/immuno6040076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immuno, online erschienen am 06.11.2026. Verfasst von Amankeldi Sadanov und 10 weiteren Autor:innen. Die Arbeit nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education, Kazakhstan.
Abstract (Originalsprache)
Fungal infections and their pathogens have become a significant global public health issue, with 6.5 million invasive cases and 3.8 million deaths annually, particularly affecting individuals with weakened immune systems or underlying health conditions. This narrative review aims to describe current knowledge (2010–2026) on the most clinically relevant fungal pathogens (WHO list) and traditional antifungals and innovations, including rezafungin, ibrexafungerp, olorofim, and isavuconazole. Kazakhstan’s roseofungin presents as a broad-spectrum polyene for candidiasis and dermatomycoses, limited by producer productivity; however, it is promising for local markets. The review also emphasizes novel antifungal probiotic methods and their potential use as adjuncts to conventional therapy. Antifungal probiotics (Lactobacillus spp., Saccharomyces boulardii) reduce Candida biofilms and colonization as adjunctive therapies, corroborated by randomized controlled trials and meta-analyses. The rising resistance to current antifungal drugs, along with toxicity, limited pharmacological diversity, and restricted access in numerous places, continues to impede the successful management of mycoses.
Förderung
- Ministry of Science and Higher Education, Kazakhstan
Zitieren
APA
Sadanov, A., Baimakhanova, B., Shorabayev, E., Bazaraliyeva, A., Turgumbayeva, A., Trenozhnikova, L., Balgimbayeva, A., Baimakhanova, G., Orasymbet, S., Sultanova, A., & Ross, S. A. (2026). Human Fungal Infections: Pathogens, Current Antifungal Therapies, Antifungal Resistance, and Probiotics: A Literature Review. Immuno, 6(4), 76. https://doi.org/10.3390/immuno6040076
Vancouver
Sadanov A, Baimakhanova B, Shorabayev E, Bazaraliyeva A, Turgumbayeva A, Trenozhnikova L, et al. Human Fungal Infections: Pathogens, Current Antifungal Therapies, Antifungal Resistance, and Probiotics: A Literature Review. Immuno. 2026;6(4):76. doi:10.3390/immuno6040076
BibTeX
@article{Sadanov2026,
author = {Sadanov, Amankeldi and Baimakhanova, Baiken and Shorabayev, Erik and Bazaraliyeva, Aigerim and Turgumbayeva, Aknur and Trenozhnikova, Lyudmila and Balgimbayeva, Asya and Baimakhanova, Gul and Orasymbet, Saltanat and Sultanova, Aisha and Ross, Samir A.},
title = {Human Fungal Infections: Pathogens, Current Antifungal Therapies, Antifungal Resistance, and Probiotics: A Literature Review},
journal = {Immuno},
year = {2026},
volume = {6},
number = {4},
pages = {76},
doi = {10.3390/immuno6040076}
}
EUVIMED